US 11,944,612 B2
Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Eleanor L. Ramos, South San Francisco, CA (US); Joshua Eli Lehrer-Graiwer, South San Francisco, CA (US); Athiwat Hutchaleelaha, South San Francisco, CA (US); and Naveen Bejugam, South San Francisco, CA (US)
Assigned to Global Blood Therapeutics, Inc., South San Francisco, CA (US)
Filed by Global Blood Therapeutics, Inc., South San Francisco, CA (US)
Filed on Aug. 5, 2022, as Appl. No. 17/881,874.
Application 17/881,874 is a continuation of application No. 17/559,156, filed on Dec. 22, 2021, abandoned.
Application 17/559,156 is a continuation of application No. 17/326,045, filed on May 20, 2021, abandoned.
Application 17/326,045 is a continuation of application No. 15/368,142, filed on Dec. 2, 2016, granted, now 11,020,382.
Claims priority of provisional application 62/375,832, filed on Aug. 16, 2016.
Claims priority of provisional application 62/263,554, filed on Dec. 4, 2015.
Prior Publication US 2022/0378770 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4439 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01)
CPC A61K 31/4439 (2013.01) [A61K 9/1605 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01)] 23 Claims
 
1. A capsule dosage form comprising:
(i) from about 65% to about 93% w/w of Compound 1;

OG Complex Work Unit Chemistry
(ii) from about 2% to about 10% w/w a binder;
wherein w/w is relative to the total weight of the formulation, excluding the weight of the capsule, and
wherein the compound 1 is in a crystalline ansolvate form that is characterized by at least four X-ray powder diffraction peaks (Cu Kα radiation) at 13.37°, 14.37°, 19.95° and 23.92° 2θ, each peak is ±0.2° 2θ.